Supplemental Information

12 Months Ended

Dec. 31, 2023

Supplemental Balance Sheet Information [Abstract]

Cash, Cash Equivalents and Restricted Cash

The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands):


	2023		2022		2021
Cash and cash equivalents	$	944,073	$	1,315,792	$	1,550,004
Restricted cash included in prepaid expenses and other current assets (1)	4,789		8,221		—
Restricted cash included in other non-current assets (1)	40,722		45,568		42,924
Total cash, cash equivalents and restricted cash	$	989,584	$	1,369,581	$	1,592,928

(1)Includes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	As of December 31,
	2023		2022
Notes receivable (Note 4)	$	12,293	$	—
Prepaid expenses	10,360		18,145
Prepaid insurance and insurance recoveries	10,063		16,960
Restricted cash	4,789		8,221
Other receivables	1,546		1,561
Security deposits	318		2,084
Inventory	46		4,364
Other current assets	362		487
Prepaid expenses and other current assets	$	39,777	$	51,822

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following (in thousands):


	As of December 31,
	2023		2022
Lab equipment	$	147,185	$	183,292
Leasehold improvements	71,564		125,307
Buildings and facilities	47,034		46,019
Construction in progress	15,830		23,426
Computer equipment and software	14,780		15,219
Furniture and fixtures	6,458		8,206
Land	6,060		6,060
Total property, plant, and equipment	308,911		407,529
Less: Accumulated depreciation and amortization	(120,718)		(92,756)
Property, plant, and equipment, net	$	188,193	$	314,773

Depreciation and amortization expense for the years ended December 31, 2023, 2022 and 2021 totaled $54.8 million, $36.9 million and $26.9 million, respectively.

During the year ended December 31, 2023, the Company identified excess lab equipment at two of its facilities whereby the assets were sold, classified as held for sale or otherwise impaired, resulting in aggregate impairment losses of $25.2 million, included in general and administrative expense in the consolidated statement of operations and comprehensive loss.

Other Non-Current Assets

Other non-current assets consisted of the following (in thousands):


	As of December 31,
	2023		2022
Restricted cash	$	40,722	$	45,568
Notes receivable (Note 4)	13,601		37,660
Finance lease right-of-use assets, net	2,230		3,256
Other assets	1,502		2,241
Other non-current assets	$	58,055	$	88,725

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	As of December 31,
	2023		2022
Professional fees and securities litigation costs	$	27,884	$	12,178
Operating lease liabilities	18,878		28,032
Contingent consideration liability	18,468		6,378
Employee compensation and benefits	15,678		19,441
Deferred other income	4,009		—
Biosecurity costs	3,564		15,401
External research and development expenses	2,739		1,844
Property and equipment	2,667		11,624
Finance lease liabilities	1,055		1,300
Lab supplies	861		3,434
Other current liabilities	14,248		15,062
Accrued expenses and other current liabilities	$	110,051	$	114,694

Supplemental cash flow information

The following table presents supplemental cash flow information for each reporting period (in thousands):


	Year Ended December 31,
	2023		2022		2021
Cash paid for interest	$	83	$	92	$	2,370
Cash paid for income taxes	670		—		61
Non-cash investing and financing activities:
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842	$	—	$	147,744	$	—
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842	—		3,397		—
ROU assets obtained in exchange for new operating lease liabilities	27,668		79,984		—
ROU assets obtained in exchange for new finance lease liabilities	—		1,729		—
Purchase of minority interest in Cooksonia	—		7,390		—
Purchases of equipment through capital leases	—		—		1,981
Lease financing obligation for build-to-suit lease	—		—		6,120
Purchases of property and equipment included in accounts payable and accrued expenses	2,915		12,881		1,815
Equity received in related parties	—		8,873		61,554
Convertible financial instruments received for Cell Engineering services	4,542		29,074		—
Equity securities and warrants received for Cell Engineering services	17,450		3,423		10,000
Conversion of convertible promissory notes to preferred stock	—		—		195
Non-cash consideration paid for the acquisition of Zymergen	—		231,750		—
Common stock issued for acquisitions	6,820		40,382		15,087
Acquisition date fair value of contingent consideration liability	—		19,912		8,760
Acquisition date fair value of warrant liabilities	—		—		194,453
Settlement of contingent consideration liability	8,896		—		—
Equity issuance costs in accounts payable and accrued expenses	—		578		—